Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

AbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, hepatitis C, women"s health, oncology, and neuroscience. AbbVie also offers treatments for diseases including multiple sclerosis, parkinson"s, and alzheimer"s disease.
Website: abbvie.com


  • Good financial results growth rate 14.1% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-7.9%)
  • Dividend yield for the last twelve months 3.0%
  • Free cash flow yield -1.7% (LTM)
  • Share price is 60.3% higher than minimum and 1.9% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (37.5x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $11.0 mln (-0.003% of cap.)

Key Financials (Download financials)

Ticker: ABBV
Share price, USD:  (+0.3%)212.47
year average price 189.81  


year start price 192.86 2024-09-05

min close price 164.99 2024-11-15

max close price 216.66 2025-03-10

current price 211.86 2025-09-04
Common stocks: 1 768 480 508

Dividend Yield:  3.0%
FCF Yield LTM: -1.7%
EV / LTM EBITDA: 37.5x
EV / EBITDA annualized: 21.6x
Last revenue growth (y/y):  +6.6%
Last growth of EBITDA (y/y):  +21.5%
Historical revenue growth:  +0.7%
Historical growth of EBITDA:  -16.5%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 375 749
Net Debt ($m): 64 059
EV (Enterprise Value): 439 808
EBITDA LTM ($m): 11 713
EV / LTM EBITDA: 37.5x
Price to Book: 62.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-09-04fool.com

Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years?

2025-09-01zacks.com

Investing in the Age of Longevity: Silver Economy Stocks in Focus

2025-08-31seekingalpha.com

Wall Street Week Ahead

2025-08-31fool.com

5 High-Yield Dividend Stocks I Plan on Holding for the Next 10 Years or Longer

2025-08-30fool.com

The Smartest Dividend Stocks to Buy With $500 Right Now

2025-08-29seekingalpha.com

AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin

2025-08-27seekingalpha.com

Best Dividend Aristocrats For September 2025

2025-08-26seekingalpha.com

AbbVie: Plenty Of Positives

2025-08-26zacks.com

ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression

2025-08-24seekingalpha.com

Best Dividend Kings: August 2025
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data